Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors.
The research pinpoints important genetic errors these deadly tumors have in common.
“…the new information could help doctors find ways to identify which patients may develop aggressive tumors…”
“This study could aid the search for better therapies to treat aggressive prostate cancer,” says co-first author Christopher A. Maher, an associate professor of medicine and an assistant director at The McDonnell Genome Institute at the Washington University School of Medicine in St. Louis. “More immediately, the new information could help doctors find ways to identify which patients may develop aggressive tumors, and help guide their treatment decisions.”
Thinking beyond proteins
More than 160,000 cases of prostate cancer are diagnosed each year in the US. While some 80 percent of prostate cancer patients have tumors that are slow-growing and have effective treatment options, about 20 percent of such patients develop the most aggressive forms of the disease—the focus of the new study.
Most genetic studies of prostate cancer have focused on parts of the genome that control what proteins a tumor manufactures. Proteins act like the machinery of cells. When they function properly, proteins perform cellular tasks required for good health. But when proteins don’t work properly, disease, including cancer, can result.
Still, genes that make proteins represent only one to two percent of the entire genome. The new analysis is the first large-scale study of the whole genomes—all of the DNA, including all of each tumor’s genes—of metastatic prostate tumors, and reveals that many of these tumors have problems in the sections of the genome that tell protein-coding genes what to do.
“Protein-coding genes are important, but when you focus only on them you can miss mutations in regions of the genome that regulate those genes,” Maher says.
The researchers were surprised to find that about 80 percent of the aggressive tumors studied had the same genetic alterations in a region of the genome that controls the androgen receptor, Maher says. This genetic error dialed up levels of androgen receptor on prostate cancer cells. Such receptors bind to male hormones such as testosterone and drive tumor growth.
“This was one of the most surprising findings,” says Maher, also a research member of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University. “We saw too many repeated copies of DNA in this region of the genome. In some of these patients, the androgen receptor looks totally normal. But they have too much androgen receptor because the receptor’s regulatory region is dialed up, which would be missed by the protein-coding focused sequencing studies.”
A common treatment for prostate cancer, beyond the traditional options of surgery, chemotherapy, and radiation, involves androgen deprivation therapy, in which drugs block testosterone from binding to the androgen receptor. Since prostate tumors are often hormone-driven cancers, blocking testosterone from binding this receptor slows tumor growth.
All the men in this study had tumors that developed resistance to androgen deprivation therapy, meaning the androgen receptor is always switched on, fueling the tumor, whether testosterone is present or not. Patients in this situation have no effective treatment options. The researchers showed that more than 80 percent of these patients had mutations that help explain the aggressiveness of their cancers; these genetic errors activated the androgen receptor.
The researchers also found important roles for other genes known to be involved in cancer, including those that help with DNA repair, such as TP53 and BRCA2.
The research appears in the journal Cell. Additional researchers from Washington University School of Medicine in St. Louis and the University of California, San Francisco contributed to the study.
A Stand Up To Cancer-Prostate Cancer Foundation Prostate Cancer Dream Team Award and the American Association for Cancer Research, the scientific partner of SU2C, supported the research.
The Goldberg-Benioff Research Fund for Prostate Cancer Translational Biology; the Stand Up To Cancer-Prostate Cancer Foundation Prostate Cancer Dream Award; several Prostate Cancer Foundation Challenge Grants; a V Foundation Scholar Grant; a BRCA Foundation Young Investigator Award; Department of Defense (DOD) grants; an Early Detection Research Network Grant; Prostate SPORE Grants; a National Cancer Institute (NCI) T32 training grant; and several Prostate Cancer Foundation Young Investigator Awards also supported the work.